UPIN & IPIN: TRUYỀN THUYẾT THẦN ĐAO

Gain actionable insight from technical analysis on financial instruments, to lớn help optimize your trading strategies

Bạn đang xem: Upin & ipin: truyền thuyết thần đao


Previous Close0.0868
Open0.0818
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0818 - 0.0859
52 Week Range0.0415 - 0.2790
Volume13,490
Avg. Volume183,427

Market Cap8.941M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A

Fair Value is the appropriate price for the shares of a company, based on its earnings và growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company và holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Xem thêm: Hồ Ngọc Hà ) - Ho Ngoc Ha Is Making A Documentary About Love


*


Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease & cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen & Neulasta, và Enbrel và Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 và markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), & Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), & Amgevita (biosimilar Humira).
Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen & Aranesp, immune system boosters Neupogen và Neulasta, and Enbrel & Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) và Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), & Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), và Amgevita (biosimilar Humira).